Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Low doses of interferon alpha result in more effective clinical natural killer cell activation.
B S Edwards, … , R C Fuhlbrigge, E C Borden
B S Edwards, … , R C Fuhlbrigge, E C Borden
Published June 1, 1985
Citation Information: J Clin Invest. 1985;75(6):1908-1913. https://doi.org/10.1172/JCI111905.
View: Text | PDF
Research Article Article has an altmetric score of 3

Low doses of interferon alpha result in more effective clinical natural killer cell activation.

  • Text
  • PDF
Abstract

To define critical parameters concerning interferon (IFN) effects upon natural killer (NK) cells in vivo, we gave cancer patients serial weekly intramuscular injections of purified lymphoblastoid IFN in six doses ranging from 10(5) to 3 X 10(7) U. Dose sequences were determined by randomly allocating patients to one of six levels in a latin square ordering scheme. NK cell stimulation, a threefold peak increase above preinjection levels of cytolysis (P = 0.022), occurred in peripheral mononuclear cells (PMC) sampled 24 h postinjection, of 3 X 10(6) U, but was not detectable at any dose in PMC sampled 7 d postinjection. No blunting occurred in NK cell responsiveness to repeated injection of IFN dosages a second time at or several weeks after study completion. At IFN doses of 3 X 10(6), 10(7), and 3 X 10(7) U, a negative correlation existed between the amount of IFN injected and the average extent of NK cell activation (r = -0.423, P less than 0.05). This contrasted with the progressively increasing response of NK cells to in vitro incubation with increasing concentration of up to 3,000 U/ml of IFN. Overnight culturing of PMC sampled before IFN injections resulted in a mean 1.9-fold increase in cytolytic activity (P = 0.0005) and a mean 53% decrease in variance (P = 0.024) between serial preinjection NK cell activity determinations. Cell separation procedures may, therefore, have resulted in NK cell inactivation, from which overnight culturing permitted recovery. We found that maximal NK cell activation at a low IFN dose, decreasing NK cell responsiveness at higher doses, and the need to culture PMC to efficiently detect NK cell boosting may account for disparities in reported effects of IFN on NK cell function.

Authors

B S Edwards, J A Merritt, R C Fuhlbrigge, E C Borden

×

Total citations by year

Year: 2024 2022 2021 2020 2019 2017 2016 2014 2010 2009 2008 2007 2006 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 Total
Citations: 1 1 2 1 1 2 1 2 1 1 1 1 1 2 2 1 1 3 1 1 4 2 2 5 8 9 6 4 4 71
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (71)

Title and authors Publication Year
Increased IFN-β indicates better survival in hepatocellular carcinoma treated with radiotherapy
Zhang Y, Hong W, Zheng D, Li Z, Hu Y, Chen Y, Yang P, Zeng Z, Du S
Clinical and Experimental Immunology 2024
Identification of a prognostic classifier based on EMT-related lncRNAs and the function of LINC01138 in tumor progression for lung adenocarcinoma
Xiao L, Huang Y, Li Q, Wang S, Ma L, Fan Z, Tang Z, Yuan X, Liu B
Frontiers in Molecular Biosciences 2022
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
Michelle von Locquenghien, Catalina Rozalen, Toni Celià-Terrassa
Journal of Clinical Investigation 2021
Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer
DJ Zanker, KL Owen, N Baschuk, AJ Spurling, BS Parker
Cancer Immunology, Immunotherapy 2021
Cancer Immunology: Bench to Bedside Immunotherapy of Cancers
N Rezaei
2020
Interferons α and β in cancer: therapeutic opportunities from new insights
EC Borden
Nature Reviews Drug Discovery 2019
Beyond the vicious cycle: The role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis
KL Owen, BS Parker
Molecular Immunology 2017
Interferon related pericarditis: Review
K Nishio, T Arase, H Tada, H Tachibana
World journal of cardiology 2017
Recurrent Pericarditis, an Unexpected Effect of Adjuvant Interferon Chemotherapy for Malignant Melanoma
F Ashraf, F Marmoush, MI Shafi, A Shah
Case Reports in Cardiology 2016
Interferons and Their Stimulated Genes in the Tumor Microenvironment
HJ Cheon, EC Borden, GR Stark
Seminars in Oncology 2014
The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)
H Kaufman, M Wong, G Daniels, D McDermott, S Aung, J Lowder, M Morse
Journal of Personalized Medicine 2014
Safety and Effectiveness of Interferon Alpha-2a in Treatment of Patients with Behçet's Uveitis Refractory to Conventional Treatments
G Sobacı, Ü Erdem, AH Durukan, C Erdurman, A Bayer, S Köksal, S Karagul, MZ Bayraktar
Ophthalmology 2010
Principles of Cancer Biotherapy
RK Oldham, RO Dillman
2009
Intratumoral Dendritic Cells and Chemoradiation for the Treatment of Murine Squamous Cell Carcinoma
JS Moyer, J Li, S Wei, S Teitz-Tennenbaum, AE Chang
Journal of Immunotherapy 2008
Regulation of Activated CD4+ T Cells by NK Cells via the Qa-1–NKG2A Inhibitory Pathway
L Lu, K Ikizawa, D Hu, MB Werneck, KW Wucherpfennig, H Cantor
Immunity 2007
Positive and negative regulation of Natural Killer cells: Therapeutic implications
WH Hallett, WJ Murphy
Seminars in Cancer Biology 2006
Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine
CJ Harrison, RL Miller, DI Bernstein
Vaccine 2001
Head and Neck Cancer
A Forastiere, W Koch, A Trotti, D Sidransky
New England Journal of Medicine 2001
RETRACTED: Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial
H Demiroglu, OI Özcebe, I Barista, S Dündar, B Eldem
The Lancet 2000
Mild hyperthermia modulates biological activities of interferons
J Payne, MP Nair, JL Ambrus, KC Chadha
International Journal of Hyperthermia 2000
Autoimmunity induced by interferon-α therapy for chronic viral hepatitis
F Dumoulin, L Leifeld, T Sauerbruch, U Spengler
Biomedecine & Pharmacotherapy 1999
Type I Interferons
ED Maeyer, JD Maeyer-Guignard
International Reviews of Immunology 1998
Bleomycin-induced lung injury is enhanced by interferon-α
N Berkman, RH Goldstein, R Breuer
Life Sciences 1997
Phase I Study Combining Tumor Necrosis Factor with Interferon-α and Interleukin-2
ED Eskander, HA Harvey, E Givant, A Lipton
American Journal of Clinical Oncology 1997
Common cancers—Immunotherapy and multidisciplinary therapy: Parts III and IV
WD Quan, CS Palackdharry
Disease-a-Month 1997
Weekly 5-Fluorouracil and Interferon-alfa-2b in Metastatic Cancer
WD Quan, R Casal
Cancer Biotherapy & Radiopharmaceuticals 1996
Beta-Interferon
HJ Obert
1995
Interferon as adjunctive treatment for non-metastatic renal cell carcinoma
S Takahashi, T Tanigawa, M Imagawa, H Mimata, Y Nomura, J Ogata
British Journal of Urology 1994
Basic Mechanisms of Physiologic and Aberrant Lymphoproliferation in the Skin
WC Lambert, B Giannotti, WA van Vloten
1994
Cancer Treatment An Update
P Banzet, JF Holland, D Khayat, M Weil
1994
Effects of type I-interferons on human thyroid epithelial cells derived from normal and tumour tissue
E Selzer, A Wilfing, V Sexl, M Freissmuth
Naunyn-Schmiedeberg's Archives of Pharmacology 1994
The role of interleukin-2 in the treatment of cancer patients
J Wagstaff
1993
Current Research and Clinical Management of Melanoma
L Nathanson
1993
Modulation of 2′,5′-OHgoadenylate Synthetase in Patients Treated with Alpha-Interferon: Effects of Dose, Schedule, and Route of Administration
JA Merritt, LA Ball, KM Sielaff, DM Meltzer, EC Borden
Journal of Interferon Research 1992
Interferons: Pleiotropic cellular modulators
EC Borden
Clinical Immunology and Immunopathology 1992
A phase I trial of α-interferon in combination with pentostatin in hematologic malignancies
S Bernard, P Gill, P Rosen, M Gavigan, A Steagall, E Ellingham, T Morgan, G Janic, H Ozer
Medical and Pediatric Oncology 1991
Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck
DR Vlock, J Johnson, E Myers, R Day, WE Gooding, T Whiteside, K Pelch, B Sigler, R Wagner, D Colao, D Rust
Head & Neck 1991
Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-α or interferon-α plus chemotherapy in vivo and in vitro
WR Bezwoda, T Golombick, R Dansey, J Keeping
European Journal of Cancer and Clinical Oncology 1991
Melanoma Research: Genetics, Growth Factors, Metastases, and Antigens
L Nathanson
1991
Immunotherapy of Renal Cell Carcinoma
FM Debruyne, RM Bukowski, JE Pontes, PH de Mulder
1991
The effect of recombinant interferon-alpha on lymphocyte subpopulations and HLA-DR expression on liver tissue of HBV-positive individuals
YK Yoo, JB Gavaler, K Chen, TL Whiteside, DH Thiel
Clinical & Experimental Immunology 1990
Lymphokines and cytokines as cancer treatment.Immunotherapy realized
EC Borden, PM Sondel
Cancer 1990
Biological and Clinical Effects of Interferon-βserat Two Doses
EC Borden, JJ Rinehart, BE Storer, DL Trump, DM Paulnock, AP Teitelbaum
Journal of Interferon Research 1990
New therapeutic strategies in the treatment of murine diseases induced by virus and solid tumors: Biology and implications for the potential treatment of human leukemia, AIDS, and solid tumors
RN Shen, L Lu, HE Broxmeyer
Critical Reviews in Oncology/Hematology 1990
Modulation of lymphoid cell sensitivity to interferon by thyroid hormones
M Provinciali, N Fabris
Journal of Endocrinological Investigation 1990
Generation of tumoricidal effector cells with a novel potentiator: N-[4-[(4-fluorophenyl)sulfonyl]phenyl] acetamide (CL 259,763)
BS Wang, AL Lumanglas, YI Lin, FE Durr
International Journal of Immunopharmacology 1990
Genital Papillomavirus Infections
G Gross, S Jablonska, H Pfister, HE Stegner
1990
The effect of recombinant interferon-alpha on lymphocyte subpopulations and HLA-DR expression on liver tissue of HBV-positive individuals.
Yoo YK, Gavaler JB, Chen K, Whiteside TL, van Thiel DH
Clinical & Experimental Immunology 1990
Immunological recovery and dose evaluation in IFN-α treatment of hairy cell leukemia: Analysis of leukocyte differentiation antigens, NK and 2‘,5’-oligoadenylate synthetase activity
B Nielsen, M Hokland, J Justesen, H Hasselbalch, J Ellegaard, P Hokland
European Journal of Haematology 1989
Induced Proteins in Human Peripheral Mononuclear Cells Over a Range of Clinically Tolerable Doses of Interferon-γ
DM Paulnock, KA Havlin, BM Storer, GT Spear, KM Sielaff, EC Borden
Journal of Interferon Research 1989
The role of interferons in the treatment of malignant neoplasms
JR Murren, AC Buzaid
The Yale journal of biology and medicine 1989
Immunosuppressive effects of recombinant interferon-α during long-term treatment of cancer patients
JV Teichmann, G Sieber, WD Ludwig, H Ruehl
Cancer 1989
Low-dose recombinant interferon-α in the treatment of cutaneous T-cell lympbomas
B Dreno, WY Godefroy, M Fleischmann, B Bureau, P Lioutx
British Journal of Dermatology 1989
in vivo effects of combination treatment with recombinant interferon-gamma and -alpha in metastatic melanoma
S Osanto, R Jansen, AM Naipal, JW Gratama, AV Leeuwen, FJ Cleton
International Journal of Cancer 1989
Whole blood assay for NK activity in splenectomized and non-splenectomized hairy cell leukemia patients during IFN-α-2b treatment
B Nielsen, P Hokland, J Ellegaard, H Hasselbalch, M Hokland
Leukemia Research 1989
Cancer Metastasis
V Schirrmacher, R Schwartz-Albiez
1989
Exercise and Natural Killer Cells: What is the Relationship?
LT Mackinnon
Sports Medicine 1989
IFN-treatment of B16-F1 versus B16-F10: Relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread
M Zöller
Clinical & Experimental Metastasis 1988
Interferons Affect Oxygen Metabolism in Human Neutrophil Granulocytes
K Lappegård, H Benestad, H Rollag
Journal of Interferon Research 1988
Correlation of immunomodulatory and therapeutic activities of interferon and interferon inducers in metastatic disease
PL Black, H Phillips, HR Tribble, R Pennington, M Schneider, JE Talmadge
Journal of Cellular Biochemistry 1988
Modulation of Immune Functions by Long-Term Treatment with Recombinant Interferon-α2in a Patient with Hairy-Cell Leukemia
J Teichmann, G Sieber, WD Ludwig, H Ruehl
Journal of Interferon Research 1988
Comparative study of various immunomodulators for macrophage and natural killer cell activation and antiviral efficacy against exotic RNA viruses
AJ Pinto, PS Morahan, MA Brinton
International Journal of Immunopharmacology 1988
Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias
JM Bennett, KA Foon
1988
Prolonged (6 months) treatment of chronic hepatitis B virus infection with recombinant leukocyte A interferon
V Carreño, JC Porres, I Mora, J Bartolomé, C Bas, J Gutiez, J Cortés, CH Guio
Liver 1987
Therapeutic potential of cytokines
JE Talmadge
Clinical Immunology Newsletter 1987
Changes of hepatitis B virus (HBV) markers during prolonged recombinant interferon alpha-2A treatment of chronic HBV infection
I Mora, JC Porres, J Bartolomé, JA Quiroga, J Gutiez, CH Guio, C Bas, V Carreño
Journal of Hepatology 1987
Anticarcinogenesis and Radiation Protection
PA Cerutti, OF Nygaard, MG Simic
1987
Separation of Human Natural Killer Cell Subpopulations Differentially Responsive to Interferon Potentiation
BS Edwards, RC Fuhlbrigge, EC Borden
Journal of Interferon Research 1986
Modulation of 2′,5′-Oligoadenylate Synthetase in Patients Treated with Alpha-Interferon: Effects of Dose, Schedule, and Route of Administration
JA Merritt, LA Ball, KM Sielaff, DM Meltzer, EC Borden
Journal of Interferon Research 1986
A Biological Approach to Optimize Interferon Treatment in Hairy Cell Leukemia
G Gastl, W Aulitzky, H Tilg, K Nachbaur, J Troppmair, R Flener, C Huber
Immunobiology 1986
Alpha interferon in the treatment of hematologic malignancies
MS Roth, KA Foon
The American Journal of Medicine 1986

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 2 patents
11 readers on Mendeley
See more details